8th Apr 2026 14:06
Coiled Therapeutics PLC - London-based clinical stage oncology company - Giving a clinical trial update, company announces that regarding advanced solid tumour cancers, its brain-penetrant inhibitor AO-252 delivered an 80% clinical benefit rate when transitioned to a twice-daily dosing regimen, compared to 40% observed in the once-daily cohort. The firm says 80% of evaluable patients in the twice-daily cohort achieved tumour stabilisation or regression, with treatment durations exceeding six months. "This substantially outperforms the two to three month benchmark typically seen with salvage therapy in this heavily pre-treated population," Coiled adds. Read More
